Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings

Authors: Joshua M Chevalier* (a), Megan A Hansen* (a), Kyra H Grantz (a, b), Birgitta Gleeson (b), Benjamin Blumel (b), Veronicah Chuchu (b), Shaukat Khan (b), Ntombi Sigwebela (c), Gwendoline Chimhini (d), Felicity Fitzgerald (e), Cecilia Ferreyra† (b), Brooke E Nichols† (a, b, f)

Affiliations:
a. Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
b. FIND, Geneva, Switzerland
c. FIND, Cape Town, South Africa
d. Department of Child Adolescent and Women's Health, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe
e. Department of Infectious Diseases, Imperial College London, London, United Kingdom
f. Department of Global Health, Boston University School of Public Health, Boston, MA, USA

Correspondence: BE Nichols – brooken@bu.edu

*Equal contribution
†Equal contribution

Abstract:

Introduction

Sepsis accounts for up to 50% of neonatal deaths in resource-limited countries. Accurate and timely diagnosis could improve clinical outcomes, reduce inappropriate antibiotic use, and provide healthcare cost savings. We aimed to identify the minimum technical specifications and cost required of a point-of-care test (POCT) for neonatal sepsis to be clinically useful in hospital and community levels in low-resource settings.

Methods

We modeled the diagnosis and treatment of two cohorts: hospitalized neonates and infants presenting to primary health care facilities with suspected sepsis. We compared health outcomes, including mortality, length of hospital stays, and acquisition of healthcare-associated infections (HAIs), under a POCT compared to empiric treatment and blood culture across varying test performance, prevalence of bacterial infection and discharge eligibility. A threshold health economic analysis was performed to determine the allowable POCT price to remain cost neutral to the healthcare system.

Results

A POCT could lead to a net reduction in neonatal deaths at both the hospital level (up to 19% of deaths averted compared to baseline) and community level (up to 76% deaths averted) through faster initiation of appropriate therapy and reducing unnecessary hospitalizations and HAIs. Healthcare costs could be reduced substantially with implementation of a POCT (17%–43% of baseline costs saved in hospital and 48%–81% saved in primary healthcare settings across the range of analyzed scenarios), suggesting a POCT costing up to $21 in hospitals and $3 in community settings could be cost neutral.

Conclusions

A POCT for neonatal sepsis, even with imperfect accuracy, could substantially improve clinical outcomes by improving time to diagnosis, while also supporting antibiotic de-escalation and stewardship and lowering healthcare costs. However, high clinical sensitivity is required to avoid causing deaths through missed diagnoses due to false negative results and delayed antibiotic initiation.

Key Questions

What is already known on this topic?

It is known that neonatal sepsis and possible serious bacterial infections in infants are a serious cause of mortality; however, diagnosis to provide proper treatment and care remains difficult.

What does this study add?

This study generates evidence on what the technical specifications and costs are required of a novel point-of-care test through mathematical modeling.

How might this study affect research, practice, or policy?

These results can be used as criteria to guide the development of a novel point-of-care test for neonatal sepsis and bacterial infection in infants.

Introduction

Sepsis is a significant cause of neonatal (0–28 days-old) mortality worldwide, accounting for 7.3% of all neonatal deaths(1). Low- and middle-income countries with limited resources bear a disproportionate burden of neonatal sepsis, with infections presenting both in hospital and primary health care (PHC) settings (2).

Diagnosing neonatal sepsis is difficult due to nonspecific symptoms (fever, vomiting, irritability, etc.) and a lack of readily available, easy-to-use diagnostic tests. Diagnostic testing is particularly challenging in resource-limited settings, as many lack laboratory infrastructure to routinely perform blood culture as a first step in the etiologic diagnosis and treatment of sepsis (3,4). Microbiology services, including culture and antibiotic susceptibility testing, are typically only available at higher-level facilities (5). Even where microbiology services are available, the challenge of sufficient blood-draw volume, long turnaround times, and poor quality pathogen identification and antibiotic susceptibility testing can limit the clinical utility of test results (6).

Without timely and adequate diagnosis, hospitalized neonates or infants suspected of sepsis are treated empirically with broad-spectrum antibiotics, potentially leading to overuse of antibiotics and unnecessary hospitalization of those without bacterial infections. Antibiotic overuse in this age group can lead to morbidity and mortality, especially in low birthweight or preterm newborns, while also contributing to the growing concern of antimicrobial resistance (AMR) (7,8). Continued hospitalization of otherwise healthy neonates puts them at risk of healthcare-associated infections (HAIs) – a major cause of sepsis (9).

At the community level, there are often no diagnostic tools available for infants with possible serious bacterial infections (pSBI) (10). Current standard practice for infants with critical illness or clinical severe infection classifications of pSBI at a PHC facility is to provide a single dose of antibiotics and referral to the nearest hospital with greater access to the necessary tools for care (4,11). However, if referral is not feasible due to distance, cost, and/or time required, antibiotic injections may be provided at the PHC level (12). This broad-scale treatment and referral to higher-level care, even for infants without true bacterial infections, results in unnecessary antibiotic use and hospitalization.

New diagnostic tools to identify sepsis and pSBI in neonates and infants could greatly improve clinical management, guide referral decisions, and reduce misdiagnosis or unnecessary treatment (4,13). A diagnostic tool, whether in the form of an algorithm or a point-of-care test (POCT) for neonatal/infant sepsis must meet certain technical specifications (sensitivity, specificity) and a realistic price to be clinically useful and feasible to implement (3,4). To better understand these minimum diagnostic tool criteria and their impact on health-outcomes, we modeled the clinical cascades of neonates born in a hospital and infants presenting at PHC facilities suspected of

111 sepsis using the current standard-of-care and using a POCT with same day results, similar to a
112 rapid diagnostic test. We then conducted a threshold health economic analysis to determine the
113 prices at which implementation of a POCT would be cost neutral to the health system. This
114 analysis provides important evidence to guide the development, implementation, and evaluation
115 of novel diagnostic tools for neonatal sepsis.
116
Methods
117
118
To evaluate the potential impact of a true POCT for neonatal sepsis, we modeled diagnosis and
clinical care of two cohorts with pSBI: 1) hospital-born neonates 0–28 days of age and 2)
0–59 days of age presenting for care at the PHC level. Both models are parameterized using data
from India and Uganda, where the best data are available, and lower-income multi-country
implementation studies (**Table 1**). Both models were built using R version 4.3.1, and analyses
were conducted using R and Microsoft Excel version 16.81. Since modeling methods were used,
patients or the public were not involved in the design, conduct, reporting, or dissemination plans
of our research.
127
128 *Cohort 1: Hospitalized neonates*
129
The modeled population consisted of 1,000 hospital-born neonates suspected of sepsis due to risk
factors (early gestational age, low birthweight) or clinical signs indicative of sepsis (fever,
difficulty breathing, inconsistent heart rate). We varied the prevalence of true bacterial sepsis
(i.e., prevalence of culture-positive sepsis). AMR infections, which accounted for 50% of all
sepsis cases, were associated with a nearly doubled case fatality rate (CFR) compared to
antibiotic susceptible infections. Relevant population parameters are summarized in **Table 1**.
Figure 1A displays the testing and clinical care cascade of the modeled population.
137
Under the baseline standard-of-care, all neonates with suspected sepsis immediately received
empiric antibiotic therapy and had a blood culture sample taken. We assumed that not all
suspected cases in need of blood culture would receive it (due to resource limitations or
insufficient blood-draw volume), meaning blood culture could only be completed for a portion of
the cohort, with results returned after 48 hours. Under the POCT intervention, all neonates with
suspected sepsis were tested using the POCT, and only those with a positive result immediately
initiated antibiotics.
145
146 We considered varying proportions of neonates without true bacterial sepsis eligible for
147 discharge after clinical evaluation and a negative result (blood culture or POCT) to represent
148 well presenting neonates. Discharge eligibility ranged (23%, 35%, 58%) based on the number of
149 neonates discharged within two, three, or five days from a neonatal intensive care unit (NICU)
150 (14). We assumed neonates with a false negative result remained hospitalized based on their

clinical presentation and received additional diagnostic testing. This created a delay to antibiotic therapy, resulting in two additional days spent in the hospital and a 47% increase in the CFR (15,16). Neonates without a true bacterial infection who received antibiotic therapy from empiric treatment or false positive results and remained hospitalized were at risk of antibiotic-related morbidities and HAIs. Neonates with a true bacterial infection (true positive) had an average hospital stay of 16 days, while neonates without infection (false positive) had an average stay of seven days (14). Neonates who contracted an HAI spent an additional 11 days in the hospital, for a total stay of 18 days (17).

Cohort 2: Infants in primary health care facilities

At the community level, a modeled population of 5,000 infants (0–59 days of age) presented to PHC facilities with pSBI (**Table 1**). Infants presenting with illness were either referred to a higher-level care facility or received treatment on-site. The three categories of pSBI used by the World Health Organization (WHO) were included in the model (from greatest to least severity): critical illness, clinical severe infection (characterized by presence of at least one sign of severe infection), and fast breathing, defined as a respiratory rate >60 breaths/minute; modeled infants were defined using these categories (11,18). Each category of pSBI had an assumed underlying probability of true bacterial infection, which was varied in this analysis. Bacterial prevalence was parameterized as lower in fast breathing infants and higher in critically ill infants, compared to infants with clinical severe infection, reflecting how pSBI severity is correlated with true bacterial infection (19).

Under the standard-of-care, per WHO guidelines, fast breathing infants 7–59 days of age were treated on-site with oral amoxicillin, while infants with a clinical severe infection and critical illness were referred to inpatient care with a pre-referral dose of antibiotics (10) (**Figure 1B**). When referral was not feasible for infants with a clinical severe infection or critical illness, we assumed they were treated on-site for up to seven days with WHO-recommended antibiotic regimens. The probability of accepting referral to hospitalization (17%–90%) was varied to reflect differently resourced contexts (11). CFRs for each category of pSBI were derived from the literature (**Table 1**).

Using the POCT, all infants presenting with critical illness received a referral and a single dose of antibiotics regardless of their POCT result, while all fast-breathing infants were treated on-site without referral based on their POCT result. Infants presenting with a clinical severe infection were only referred for higher-level care, with one dose of antibiotics, if their POCT result was positive; otherwise, those with a negative POCT were monitored on-site. False positive infants with clinical severe infection received referral and treatment, while false negatives had an assumed four-hour delay to antibiotic initiation, leading to an increased CFR (13,17).

Upon referral acceptance, infants entered the hospital model (**Figure 1A**) without additional
testing with the POCT. An assumed proportion underwent standard blood culture testing, leading
to discharge or continued antibiotic therapy. Hospitalized infants without a true underlying
bacterial infection were at risk of HAIs, experiencing a higher CFR compared to community
borne infections. These CFRs differed from those in the hospital model because different clinical
populations considered in each model (**Table 1**). Discharge eligibility among community
referred infants without bacterial infection was held constant at 58%.

Outcomes and Sensitivity Analysis

Modeled outcomes included the number of neonatal or infant deaths, days spent hospitalized,
number of HAIs, number of accepted hospital referrals, and antibiotic-associated morbidities.
Diagnostic impact was quantified as the percent reduction in deaths and hospital days, and the
number of HAIs and antibiotic-associated morbidities prevented through POCT use.

Diagnostic impact was assessed across a range of POCT sensitivities (80%–100%) and
specificities (70%–100%). Several sensitivity analyses were performed to understand the
performance of the POCT across various settings. In addition to discharge eligibility and referral
acceptance, true bacterial prevalence was varied among pSBI cases (6%, 12%, 24%) and the risk
of contracting an HAI (5%–20%) during the entire length of stay in both models. In the
community level analysis, the CFR of HAIs was varied (12%, 29%).

Economic Analysis

A threshold health economic analysis was performed to determine the total costs of care at
baseline and with the POCT to determine at which price the POCT would be cost neutral to the
healthcare system. Total costs of inpatient care in India and Uganda, representing different
contexts, were gathered from the provider perspective and inflated to 2023 USD (21,22). The
estimated cost of treatment and care for a single day in a tertiary hospital in India was $118 for
neonates with a true bacterial infection, and $96 for those without (21). In Uganda, daily
hospitalization costs for true bacterial infection was $39 and $31 for neonates without infection
(23). Healthy infants did not contribute any additional costs upon discharge. The maximum
allowable cost for a POCT in a hospital setting was calculated by dividing hospitalization costs
saved by the new diagnostic by the total number of POCTs administered to achieve cost savings.

The maximum allowable cost of a POCT at PHCs was also determined using cost savings of
community management and antibiotics. Data from the literature estimates that the cost of one
course of oral amoxicillin at a PHC in India to cost $1.29, and a single visit to a PHC facility to
cost $1.88 (21,24). From the provider perspective, an infant outpatient visit to a hospital after
receiving a referral was estimated to be $18.16 (24). Inpatient care costs at a hospital following

referral were the same as described above for the hospital model. Healthcare costs in Uganda
were used as a sensitivity analysis to represent other resource-limited settings, to identify how
the costs of healthcare in different settings may reflect the maximum allowable cost for a POCT
to remain cost neutral. In Uganda, community care and referral costs were reduced by 33% (23).
We also performed this economic analysis excluding infants with critical illness, as their POCT
results did not change clinical practice in the model.

Table 1. Model parameters for hospital and community settings. *CFR: Case Fatality Rate*

Parameter	Value (%)
Hospital Model	
Prevalence of culture-positive sepsis among suspected cases (19,25) - *High* - *Moderate* - *Low*	23.6 11.8 5.9
Proportion of infections which are antimicrobial resistant (6)	49.96
Proportion of suspected cases receiving blood culture (19)	59.51
Blood culture sensitivity/specificity (26)	66.67/100
Probability of antibiotic-related morbidities among antibiotic-treated children (26)	27.71
Probability of acquiring hospital-associated infection during hospitalization among children without prior infection (27)	5, 10, 15, 20
CFR*, no infection (6)	8.78
CFR*, antibiotic susceptible infection (6)	29.00
CFR*, antimicrobial resistant infection (6)	54.51
CFR*, delayed antibiotic initiation (15)	68.16
CFR*, antibiotic-associated mortality (28)	0.88
Community Model	
Possible serious bacterial infection (11,12) - *Proportion fast breathing (11)* - *Proportion clinical severe infection (11)* - *Proportion critical illness (11)*	38.72 53.94 7.34
Bacterial prevalence (6,19,25) - *Weighted average (0.5x, 1.0x, 2.0x)* - *Fast breathing (0.5x)* - *Clinical severe infection (1x)* - *Critical illness (2x)*	5.2, 10.4, 20.8 3.0, 5.9, 11.8 5.9, 11.8, 23.6 11.8, 23.6, 47.2
CFR* (community treated—pSBI) (11) - *Fast breathing* - *Clinical severe infection* - *Critical illness*	0.10 1.90 14.6
CFR* (hospital-treated) (11,19,29) - *Non-bacterial illness* - *True bacterial infection* - *Healthcare-associated infection*	2.6 11.5 12.0, 29.0
Referral acceptance (11,12)	17, 37, 69, 90

Results

Health outcomes of hospitalized neonates following POCT implementation

In the hospital cohort, all neonates suspected of sepsis received empiric antibiotic therapy and 60% received blood culture. Blood culture results led to 5%–13% of neonates without a true infection to be discharged early, depending on underlying discharge eligibility (23%–58%). The final mortality rate among neonates who had or developed infection was 41.7%.

When HAI risk was high (20% total risk), a POCT for neonatal sepsis in hospitals led to a net reduction in neonatal deaths (0.3%–19.4% of deaths averted compared to baseline) at all test sensitivities (80%–100%) and specificities (70%–100%) under the varying modeled proportions of bacterial prevalence and discharge eligibility (**Figure 2B**). The percentage of neonatal deaths prevented increased as POCT sensitivity increased, limiting false negatives and reducing delays to antibiotic initiation for infected neonates.

The percentage of neonatal deaths prevented with a POCT was greater with lower levels of underlying bacterial prevalence (6%) and larger proportions of neonates eligible for discharge (58%). In these contexts, test specificity was particularly important to rule out infection among otherwise well-presenting neonates. Increasing test specificity led to greater percent reductions in HAIs due to earlier discharge of neonates without infection and greater reductions in antibiotic-associated morbidities due to fewer false positive results (**Figure S1–S2**). The impact of the POCT increased when HAI risk was higher (20% overall risk vs. 5%), as HAIs constituted 9%–33% of total infection related deaths when risk was low versus 28%–66% when risk was high (**Figure 2**).

Yet, in some contexts test sensitivity was the key driver of diagnostic impact. In settings with low HAI risk (5%) and discharge eligibility (23%), but high bacterial prevalence (24%), excess deaths occurred with the POCT compared to baseline (0.2%–1.6% relative increase) when sensitivity was below 85% due to increasing false negative results and subsequent delays in antibiotic therapy among infected neonates. With a test sensitivity of 85%, specificity greater than 80% was required to avoid increases in mortality across all contexts (**Figure 2A**).

Earlier discharge leading to reduced HAI opportunity, resulted in a net reduction in hospital days. The total number of hospital days was reduced by 8.2%–50.9% with POCT use (**Figure S3**). The percent reduction in hospital days followed similar trends to neonatal deaths, with respect to test specifications, discharge eligibility, and bacterial prevalence, but was not significantly impacted by HAI risk.

Health outcomes of community-presenting infants following POCT implementation

In the modeled PHC cohort of 5,000 infants with pSBI, the proportion of infants correctly referred at baseline (i.e., infants with true bacterial infection) varied from 17% to 33% as the underlying bacterial prevalence increased (6%–24%). The proportion of correct referrals increased from 17% at baseline to 38% upon POCT implementation with the lowest modeled test specifications (80% sensitive, 70% specific) when bacterial prevalence was low and from 33% to 58% when bacterial prevalence was high (**Figure S4**). The relative impact of the POCT on appropriate referrals largely relied on high test specificity which led to more correct referrals.

At baseline, 13–50 infant deaths occurred in PHC clinics and hospitals per 1,000 pSBI episodes across all modeled scenarios (**Figure S5**). Mortality increased as underlying bacterial prevalence and referral acceptance increased. Increasing referral acceptance led to increased hospital admission of infants without bacterial infection, posing risk of HAIs. HAI deaths constituted between 0.6%–44.7% of total deaths at baseline, depending on referral acceptance, bacterial prevalence, HAI acquisition rate, and associated CFRs within the hospital setting (**Figure S6**).

A POCT to inform hospital referrals reduced total infant deaths, relative to baseline, when test sensitivity and specificity were sufficiently high (**Figure 3**). At low levels of bacterial prevalence and high levels of referral acceptance, and when HAI risk (20%) and mortality (29%) were high, a POCT with high sensitivity and specificity could reduce infant deaths by up to 70% (**Figure 3B**). However, when sensitivity and specificity were low, there was an increase in deaths (3.5%– 48% more deaths compared to baseline) at lower levels of referral acceptance and higher levels of bacterial prevalence. This was attributed to delayed antibiotic initiation associated with a false negative POCT result causing poorer clinical outcomes. The range of scenarios in which deaths increased was greater when HAI risk and mortality were low (5% and 12% respectively) (**Figure 3A**).

To limit the number of deaths caused by false negative results, a high sensitivity of at least 90% could be combined with a lower specificity (70%) to reduce total infant deaths across most scenarios. However, under the worst-case scenarios, test sensitivity (≥98%) and specificity (≥95%) would need to be exceedingly high to avoid excess infant mortality.

Sensitivity Analysis

Univariate sensitivity analyses of parameters used in both the hospital and community models, and their relationship with the number of infant deaths averted stratified by HAI risk are shown in **Figure 4**. Sensitivity and specificity were held at 85% and 80% in the hospital model, and 90% and 70% in the community model, representing the identified necessary minimum specifications to reduce mortality across most scenarios.

317
318 At the hospital level, increasing test specificity, prompting more accurate negative diagnoses,
319 drove the reduction in neonatal deaths by discharging earlier and reducing HAIs. HAI risk also
320 substantially influenced the potential reductions in mortality; when HAI risk was low, there was
321 less potential for the POCT to prevent deaths through reductions in unnecessary hospitalization.
322
323 At the community level, the probability of referral acceptance had an outsized influence on the
324 potential impact of a POCT, dictating the potential for accurate negative diagnoses with a POCT
325 to avert unnecessary hospitalization. Overall bacterial prevalence also shaped the impact of the
326 POCT, with greater potential impact when prevalence was lower (i.e., when there were more
327 healthy infants who benefitted from accurate non-referral).
328
329 *Economic Analysis*
330
POCT implementation among hospitalized neonates led to a reduction in hospitalization days
among the cohort (**Figure S7**), generating a 17%–43% reduction in total costs of treatment and
care at various levels of bacterial prevalence, proportion of neonates eligible for discharge, and
test sensitivity and specificity. Greater relative costs were saved when bacterial prevalence was
lower (6%) compared to when prevalence was higher (24%), indicating the benefits of the
diagnostic lie largely in identifying discharge-eligible neonates without infection (**Figure S8,**
S9). However, costs saved do not perfectly mirror trends in mortality shown in **Figure 2** since
higher mortality is associated with fewer days spent in the hospital and thus lower healthcare
costs.
340
Cost savings were even more considerable with the implementation of a POCT at the community
level, saving 48%–81% of total costs of follow-up and treatment compared to baseline by
limiting inappropriate referrals and hospitalization days. Since fewer inappropriate referrals
occurred at baseline when bacterial prevalence was low, there were more cost savings with
POCT implementation. Across all bacterial prevalence and proportions of infants eligible for
discharge, cost savings increased with better test performance (higher sensitivity and/or
specificity) (**Figure S10, S11**). Excluding infants with critical illness from the threshold analysis
allowed the median cost of a POCT to increase, from $0.86–$1 in India and $0.28–$0.33 in
Uganda, across varied scenarios compared to allowable POCT costs including infants with
critical illness (**Figure S12, S13**).
351
To ensure that this test is financially feasible to implement across all settings and range of
uncertainty, our analysis indicates that a globally acceptable POCT for neonatal sepsis in a
hospital setting should not exceed $21 USD. Likewise, to ensure cost neutrality in the
community setting, the lowest of the costs saved per test administered ($3) should be selected as
the optimal cost of the POCT at the PHC level (**Table S1, S2**). These results are reported

following the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) (**Table**
S3).
359
Discussion
361
Implementation of a sufficiently accurate POCT for sepsis detection in neonates or infants at
hospital and community level facilities can reduce overall morbidity and mortality, while
remaining cost neutral when priced appropriately. Although the exact impact of a POCT heavily
depends on the specific use case implementation context, our modeling found that a test with at
least 85% sensitivity and 80% specificity for hospitalized neonates and 90% sensitivity and 70%
specificity for community-presenting infants is likely to reduce mortality.
368
If test sensitivity were to be lower than these values, deaths caused by missed diagnosis of true
sepsis cases and ensued delays in antibiotic initiation could lead to overall increases in mortality.
However, there were instances where tests of low sensitivity and high specificity, due to large
reductions in unnecessary hospitalization, antibiotic use, and HAI acquisition among uninfected
patients, could lead to declines in mortality and costs despite the increased number of false
negative diagnoses. While the overall benefits of a POCT may outweigh the consequences of
false negatives in these scenarios, a test sensitivity well above 80% should remain the diagnostic
criterion, with a sensitivity of 90% serving as an ideal standard. A POCT with a low sensitivity
would have limited utility in independently ruling out sepsis among neonates and infants.
378
Along with sensitivity, test specificity needs to be sufficiently high to reduce unnecessary
hospitalizations and HAIs. However, even a test with lower specificity will improve upon the
standard of care and can be tolerated in some contexts. In the hospital setting, a specificity of
80% combined with a sensitivity of 85% saw a net reduction in neonatal deaths. However, in the
community setting, 70% specificity with 90% sensitivity led to reduced infant deaths in most
scenarios, excluding contexts with low referral acceptance (17%) and high bacterial prevalence
(24%). Under these circumstances, even 100% specificity would be insufficient unless sensitivity
was 98%, principally speaking to the importance of evaluating contextual factors when
implementing a POCT.
388
Given the complexity in diagnosing sepsis in neonates and infants, it is likely that a POCT be
used as part of a diagnostic package, which may affect overall diagnostic impact and modify the
requirements and trade-offs between POCT sensitivity and specificity. Although a true POCT
may be difficult to develop, a near POCT may have reduced impact compared to our modeled
results by creating delays to test results. The POCT could be one component of a clinical
algorithm that includes signs, symptoms and risk factors, thereby reducing the required POCT
performance to achieve net benefits through the diagnostic algorithm. Additionally, we did not
consider the effect of positive POCT results on the timeliness to appropriate antibiotic initiation

and consequent potential improved health outcomes, compared to empiric therapy alone.
Therefore, the POCT could have benefits not captured in this analysis.
399
A key limitation of this analysis is that model parameters, assumptions, and costs were all
derived from tertiary hospital and PHC studies in India and Uganda, and thus may not perfectly
represent other resource-limited settings. For example, blood culture was assumed to be 100%
specific in diagnosing true negatives, but culture contamination is common in these settings,
thereby creating more false positive results, potentially altering health outcomes. Likewise, the
possibility of false negative results due to inadequate blood volume for optimal culture
performance is also a possibility that could impact our estimates. Additionally, the model
contains assumptions that may differ across the diverse environments where sepsis in neonates
and infants is common, including bacterial prevalence, resistance profiles, length of hospital stay,
and rates of HAIs. To account for this variability, several parameters were varied to improve
model sensitivity. While we expect relative differences between the POCT and baseline
standard-of-care to be consistent, these results should be interpreted with discretion as these
parameters continue to evolve with potential stock-outs of appropriate antibiotic treatment and
exponential growth of AMR in resource-limited settings.
414
Additionally, several simplifying assumptions regarding clinical management and outcomes
were made, which may not capture all the challenges of clinical pathways in diagnosing sepsis.
For example, infants may become lost to follow-up after PHC referral, incurring unknown health
outcomes and costs. Patients were functionally dichotomized into those who were being
appropriately treated with antibiotics and untreated; in reality, treatment of bacterial sepsis is
complex, and there are clinical benefits to continued refinement of antibiotic regimens that could
not be incorporated here. Similarly, there are other indirect and long-term benefits to
implementing POCTs that are not explicitly included in this model, including reductions in the
spread of AMR and preservation of first-line antibiotics in low-resource settings. Finally, we
assumed the POCT performed as intended with respect to sensitivity and specificity, but ignored
the possibility of invalid results, which may come with a new technology. Clarifying diagnostic
algorithms based on available and developing technologies, and the clinical management that
accompany them are a necessity for accurately costing these tools in the future.
428
This modeling analysis serves as a tool for understanding the necessary technical specifications,
which should be taken into consideration with other technical parameters (i.e., blood volume,
sample preparation guidelines, and time to result) that can be used to guide the development of a
POCT as an aid to diagnose sepsis in hospitalized neonates and community-presenting infants.
An accurate POCT could improve time to diagnosis and generate net reductions in hospital days,
HAIs, and deaths, while promoting the de-escalation of antimicrobials in resource-limited
settings. Our results displayed a critical trade-off between HAI-related deaths prevented and
those caused by a false-negative diagnosis, suggesting that a high sensitivity should be

prioritized over specificity to avoid potential delays in antibiotic initiation. Given the nature of
the settings in which the POCT will be used, its cost should not exceed $21 in a hospital setting
and $3 in a community setting.
440
441 Future research should focus on bridging the current gaps in data availability regarding the
442 occurrence and clinical management of sepsis in hospitals and community settings to generate
443 more robust and context-specific estimates of the impact of a POCT, and its downstream effect
444 on AMR. Urgent investments in diagnostics development are needed to accelerate access to
445 diagnostic solutions for the vulnerable populations most impacted by neonatal sepsis.

Author Contributions
Conceptualization: BG, CF, BEN. Data curation: JMC, MAH. Methodology: JMC, MAH, KHG, SK, BEN. Formal analysis: JMC, MAH, KHG. Investigation: JMC, MAH, BG, BB VC, KHG. Supervision: BG, CF, BB, SK, BEN, KHG. Writing – original draft: JMC, MAH. Writing – review and editing: JMC, MAH, KHG, BG, BB, VC, SK, NS, GC, FF, CF, BEN.

Acknowledgements
Not applicable.

Competing Interests
FF is a trustee of Neotree, a UK registered charity that provides technology, software information, education and support to newborn healthcare workers and medical practitioners in low resource settings (charity number: 1186748). All other authors declare no conflict of interest. The funders had no role in the design of the study, the collection, analyses, or interpretation of data, the writing of the manuscript, or the decision to publish the results.

Ethical Approval
This research utilizes publicly available data from the literature; therefore, formal ethical approval was not required. However, ethical considerations were included throughout the research process as transparency was maintained in the reporting of our modeling methodology. This statement affirms our commitment to ethical conduct in research, even in the absence of formal approval.

Data Availability Statement
We acknowledge the importance of transparent and responsible data sharing to foster scientific collaboration and advance research. All data used for this study are presented in the manuscript and gathered from publicly available literature, and therefore do not necessitate any information de-identification. For additional information, interested parties can contact JMC (j.m.chevalier@amsterdamumc.nl) or MAH (m.hansen@amsterdamumc.nl).

Funding
This work was supported via FIND by the UK Department of Health and Social Care as part of the Global AMR Innovation Fund (GAMRIF) and with support from the Ministry of Foreign Affairs of the Government of the Netherlands. GAMRIF is a One Health UK aid fund that supports research and development around the world to reduce the threat of antimicrobial resistance in humans, animals and the environment for the benefit of people in low- and middle-income countries (LMICs). The views expressed in this publication are those of the authors and not necessarily those of the UK Department of Health and Social Care. FF is supported by a Wellcome Trust Early Career Award (227076/Z/23/Z).

References

1. CME Info - Child Mortality Estimates [Internet]. [cited 2024 Oct 7]. Available from: https://childmortality.org/causes-of-death/data

2. Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global incidence and mortality of neonatal sepsis: A systematic review and meta-analysis. Vol. 106, Archives of Disease in Childhood. BMJ Publishing Group; 2021. p. 745–52.

3. Adatara P, Afaya A, Salia SM, Afaya RA, Konlan KD, Agyabeng-Fandoh E, et al. Risk Factors Associated with Neonatal Sepsis: A Case Study at a Specialist Hospital in Ghana. Sci World J. 2019;2019.

4. Kirby R, Palamountain K, Spotswood N, Goldfarb D. Use Cases Sepsis Diagnostic - Infection Prevention and Control [Internet]. Available from: https://www.unicef.org/supply/media/2946/file/sepsis-diagnostic-use-cases.pdf

5. Ombelet S, Barbé B, Affolabi D, Ronat JB, Lompo P, Lunguya O, et al. Best Practices of Blood Cultures in Low- and Middle-Income Countries. Vol. 6, Frontiers in Medicine. Frontiers Media S.A.; 2019.

6. Agarwal R, Chaurasia S, Sankar MJ, Yadav CP, Arya S, Kapil A, et al. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health. 2016 Oct;4(10):e752–60.

7. Celik IH, Hanna M, Canpolat FE, Pammi M. Diagnosis of neonatal sepsis: the past, present and future. Vol. 91, Pediatric Research. Springer Nature; 2022. p. 337–50.

8. Gude SS, Peddi NC, Vuppalapati S, Gopal SV, Ramesh HM, Gude SS. Biomarkers of Neonatal Sepsis: From Being Mere Numbers to Becoming Guiding Diagnostics. Cureus. 2022 Mar;

9. Rani U, Lewis LE, Chawla K, Naha A. Preventable contributors to the neonatal healthcare-associated infections: a uni-center analytical study from South India. F1000Research. 2022 Apr 25;11:454.

10. Organization WH. Operationalizing management of sick young infants with possible serious bacterial infection (PSBI) when referral is not feasible in the context of existing maternal, newborn, and child health programmes [Internet]. 2015. Available from: https://apps.who.int/iris/bitstream/handle/10665/259592/9789241512930-eng.pdf?sequence=1

11. Nisar YB, Aboubaker S, Arifeen SE, Ariff S, Arora N, Awasthi S, et al. A multi-country implementation research initiative to jump-start scale-up of outpatient management of possible serious bacterial infections (PSBI) when a referral is not feasible: Summary findings and implications for programs. PLoS ONE. 2022 Jun;17(6 June).

12. Roy S, Patil R, Apte A, Thibe K, Dhongade A, Pawar B, et al. Feasibility of implementation of simplified management of young infants with possible serious bacterial

infection when referral is not feasible in tribal areas of Pune district, Maharashtra, India. PLoS
ONE. 2020 Aug;15(8 August).

13.   Gleeson B, Ferreyra C, Palamountain K, Jacob ST, Spotswood N, Kissoon N, et al. A call
to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-
income countries. BMJ Glob Health. 2024 Sep 1;9(9):e015862.

14.   P K, S KK, K V. A study on the length of stay of neonates in neonatal intensive care unit
in a referral hospital in India. Int J Contemp Pediatr. 6(2):746–9.

15.   Schmatz M, Srinivasan L, Grundmeier RW, Elci OU, Weiss SL, Masino AJ, et al.
Surviving Sepsis in a Referral Neonatal Intensive Care Unit: Association between Time to
Antibiotic Administration and In-Hospital Outcomes. J Pediatr. 2020 Feb;217:59-65.e1.

16.   Sisay EA, Mengistu BL, Taye WA, Fentie AM, Yabeyu AB. Length of Hospital Stay and
Its Predictors Among Neonatal Sepsis Patients: A Retrospective Follow-Up Study. Int J Gen
Med. 2022;15:8133–42.

17.   Murki S, Vardhelli V, Deshabhotla S, Sharma D, Pawale D, Kulkarni D, et al. Predictors
of length of hospital stay among preterm infants admitted to neonatal intensive care unit: Data
from a multicentre collaborative network from India (INNC: Indian National Neonatal
Collaborative). J Paediatr Child Health. 2020 Oct;56(10):1584–9.

18.   Mukhopadhyay R, Arora NK, Sharma PK, Dalpath S, Limbu P, Kataria G, et al. Lessons
from implementation research on community management of possible serious bacterial
infection (pSBI) in young infants (0-59 days), when the referral is not feasible in Palwal
District of Haryana, India. PLoS ONE. 2021 Jul;16(7 July).

19.   Saha SK, Schrag SJ, Arifeen SE, Mullany LC, Islam MS, Shang N, et al. Causes and
incidence of community-acquired serious infections among young children in south Asia
(ANISA): an observational cohort study. The Lancet. 2018 Jul;392(10142):145–59.

20.   Weiss SL, Fitzgerald JC, Balamuth F, Alpern ER, Lavelle J, Chilutti M, et al. Delayed
Antimicrobial Therapy Increases Mortality and Organ Dysfunction Duration in Pediatric
Sepsis. Crit Care Med. 2014;42(11):2409–17.

21.   Karambelkar G, Malwade S, Karambelkar R. Cost analysis of Healthcare in a Private
sector Neonatal Intensive Care Unit in India. Indian Pediatr. 2016 Sep 8;53(9):793–5.

22.   Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for Inflation and
Currency Changes Within Health Economic Studies. Value Health. 2019 Sep;22(9):1026–32.

23.   Nichols BE, Sigaloff KCE, Kityo C, Hamers RL, Baltussen R, Bertagnolio S, et al.
Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of
drug-resistant HIV: A mathematical modelling study. J Int AIDS Soc. 2014;17(1).

24.   Chauhan AS, Prinja S, Selvaraj S, Gupta A, Muraleedharan VR, Sundararaman T. Cost
of delivering primary healthcare services through public sector in India. Indian J Med Res.
2022 Sep;156(3):372–80.

25.   Milton R, Gillespie D, Dyer C, Taiyari K, Carvalho MJ, Thomson K, et al. Neonatal
sepsis and mortality in low-income and middle-income countries from a facility-based birth
cohort: an international multisite prospective observational study. Lancet Glob Health. 2022
May;10(5):e661–72.

26.   Ahmad A, Iram S, Hussain S, Yusuf NW. Diagnosis of paediatric sepsis by automated
blood culture system and conventional blood culture. JPMA J Pak Med Assoc. 2017
Feb;67(2):192–5.

27.   Mathur P, Malpiedi P, Walia K, Srikantiah P, Gupta S, Lohiya A, et al. Health-care-
associated bloodstream and urinary tract infections in a network of hospitals in India: a
multicentre, hospital-based, prospective surveillance study. Lancet Glob Health. 2022
Sep;10(9):e1317–25.

28.   Ting JY, Synnes A, Roberts A, Deshpandey A, Dow K, Yoon EW, et al. Association
between antibiotic use and neonatal mortality and morbidities in very low-birth-weight infants
without culture-proven sepsis or necrotizing enterocolitis. JAMA Pediatr. 2016
Dec;170(12):1181–7.

29.   Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-
acquired neonatal infections in developing countries. The Lancet. 2005 Mar;365(9465):1175–
88.

Figure 1. Conceptual diagram for clinical cascade for a point-of-care test for neonatal sepsis at the primary health
care level and hospital. *POCT: point-of-care test, PHC: primary health care, FB: fast-breathing, CSI: clinical*
severe infection, CI: critical illness, HAI: hospital-associated infection
580

Figure 2. Percent reduction in neonatal deaths in a hospital setting, across modeled bacterial prevalence and
proportion of neonates eligible for discharge, by test specificity and sensitivity, when **A)** the risk of hospital-
associated infections is low (5%) or **B)** high (20%).

587　**Figure 3**. Percent of deaths averted compared to baseline when using the point-of-care test at the community level,
588　by test sensitivity, specificity, bacterial prevalence, and referral acceptance, when A) HAI risk and mortality are low
589　(5%, 12%), and B) HAI risk and mortality are high (20%, 29%)
590

Figure 4. Univariate sensitivity analysis of A) hospital model parameters or B) community model parameters and the correlated number of neonatal deaths averted, stratified by A) hospital-associated infection risk or B) hospital-associated infection risk and case fatality rate. The absolute number of deaths averted is shown on the X-axis, while the corresponding percentage is shown on the error bar label. The vertical red, dashed line represents the number of deaths averted when all other variables are held at their constant A) specificity: 80%, sensitivity: 85%, discharge eligibility: 35%, bacterial prevalence: 12% or B) specificity: 70%, sensitivity: 90%, referral acceptance: 37%, bacterial prevalence: 12%. *HAI: hospital-associated infection, CFR: case fatality rate*

23